An injectable paliperidone palmitate depot for use in treating a patient in need of psychiatric treatment selected from psychosis, schizophrenia, or bipolar disorder that has been treated with a 3-month injectable paliperidone palmitate depot, wherein said patient misses for a period of nine months or longer the next scheduled maintenance dose of the 3-month injectable paliperidone palmitate depot, by a dosing regimen comprising: administering intramuscularly in the deltoid muscle of said patient a first reinitiation loading dose of 150 mg eq. of a monthly injectable paliperidone palmitate depot; administering intramuscularly in the deltoid muscle of said patient a second reinitiation loading dose of 100 mg eq. of the monthly injectable paliperidone palmitate depot on about the 4th day to about the 12th day after administering said first reinitiation loading dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a first reinitiation maintenance dose of 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23th day to about the 37rd day after administering said second reinitiation loading dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a second reinitiation maintenance dose of from about 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23rd day to about the 37th day after administering the first maintenance additional dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a third reinitiation maintenance dose of from about 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23rd day to about the 37th day after administering the second maintenance dose; and administering intramuscularly in the deltoid or gluteal muscle of said patient from about 175 mg eq. to about 525 mg eq. of the 3-month formulation of paliperidone palmitate on about the 23rd day to about the 37th day after administering the third maintenance dose of the monthly injectable paliperidone palmitate. administering intramuscularly in the deltoid muscle of said patient a first reinitiation loading dose of 150 mg eq. of a monthly injectable paliperidone palmitate depot; administering intramuscularly in the deltoid muscle of said patient a second reinitiation loading dose of 100 mg eq. of the monthly injectable paliperidone palmitate depot on about the 4th day to about the 12th day after administering said first reinitiation loading dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a first reinitiation maintenance dose of 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23th day to about the 37rd day after administering said second reinitiation loading dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a second reinitiation maintenance dose of from about 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23rd day to about the 37th day after administering the first maintenance additional dose; administering intramuscularly in the deltoid or gluteal muscle of said patient a third reinitiation maintenance dose of from about 50 mg eq. to about 150 mg eq. of the monthly injectable paliperidone palmitate depot on about the 23rd day to about the 37th day after administering the second maintenance dose; and administering intramuscularly in the deltoid or gluteal muscle of said patient from about 175 mg eq. to about 525 mg eq. of the 3-month formulation of paliperidone palmitate on about the 23rd day to about the 37th day after administering the third maintenance dose of the monthly injectable paliperidone palmitate. <EOS>